OKYO Pharma (OKYO) to Release Earnings on Monday

OKYO Pharma (NASDAQ:OKYO) is anticipated to post its Q4 2026 results after the market closes on Monday, August 10th. Analysts expect OKYO Pharma to post earnings of ($0.04) per share for the quarter. Parties may review the information on the company’s upcoming Q4 2026 earning report for the latest details on the call scheduled for Monday, July 20, 2026 at 7:00 AM ET.

OKYO Pharma Stock Down 1.2%

NASDAQ OKYO traded down $0.02 on Monday, reaching $1.66. The stock had a trading volume of 4,603 shares, compared to its average volume of 166,284. The stock has a fifty day moving average price of $1.58 and a two-hundred day moving average price of $1.71. OKYO Pharma has a 12-month low of $1.34 and a 12-month high of $3.35.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. HC Wainwright dropped their price objective on OKYO Pharma from $7.00 to $5.00 and set a “buy” rating for the company in a research note on Monday, July 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of OKYO Pharma in a research note on Friday, July 17th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $5.67.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Citadel Advisors LLC acquired a new position in OKYO Pharma during the third quarter worth $31,000. XTX Topco Ltd bought a new stake in OKYO Pharma during the fourth quarter worth about $36,000. Finally, Renaissance Technologies LLC increased its holdings in shares of OKYO Pharma by 235.0% during the fourth quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock worth $286,000 after buying an additional 96,800 shares in the last quarter. Institutional investors own 2.97% of the company’s stock.

OKYO Pharma Company Profile

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.